Meeting
2020 ASCO Virtual Scientific Program
Safety and activity of autologous T cells with enhanced NY-ESO-1–specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-ESO).
Authors
Sandra P. D'Angelo
Memorial Sloan Kettering Cancer Center, New York, NY
Sandra P. D'Angelo , Jean-Yves Blay , Warren Allen Chow , George D. Demetri , Fiona Thistlethwaite , Shiraj Sen , Albiruni Ryan Abdul Razak , John B. A. G. Haanen , Jonathan Christopher Noujaim , Melissa Lynne Johnson , Theodore Willis Laetsch , Victoria L. Chiou , Laura Pearce , Thomas H. Faitg , Ran Ji , Laura A. Johnson , Aiman M. Shalabi , Katherine Anne Thornton , Crystal Mackall , Brian Andrew Van Tine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03967223
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS11571)
DOI
10.1200/JCO.2020.38.15_suppl.TPS11571
Abstract #
TPS11571
Poster Bd #
459
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).
First Author: Sandra P. D'Angelo
Poster
2022 ASCO Annual Meeting
![ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296].](https://d201v5jt9ylckg.cloudfront.net/288/14355/213211/213211_A1227_poster_pv.jpg)
ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296].
First Author: Dejka M. Araujo
Poster
2021 ASCO Annual Meeting
Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).
First Author: Adam Jacob Schoenfeld
Poster
2021 ASCO Annual Meeting
Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis.
First Author: Sandra P. D'Angelo